Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
54 Results for "
asthma model
" in MedChemExpress (MCE) Product Catalog:
Products (54)
54 Results for "asthma model" in MCE Product Catalog:
Cat. No.: HY-118156
CAS No.: 155238-60-1
L-699333 is a 5-lipoxygenase (5-LO) inhibitor belonging to the thieno[2,3,4-cd]indole class. This compound has a 2-ethoxybutyric acid side chain and is a potent inhibitor of the biosynthesis of 5-HPETE and LTB4 produced from human 5-LO, with ICm values of 22 nM, 7 nM, and 3.8 pM for human neutrophils and whole blood, respectively. L-699333 has shown anti-inflammatory and antiasthmatic effects in a variety of animal models, including rat pleurisy models, antigen-induced wheezing models, and awake macaque and sheep asthma models. Its inhibition of 5-LO is highly selective, with higher ICm values or stronger competitive inhibition in FLAP binding assays compared to inhibition of human 15-LO, porcine 12-LO, and ram epididymal cyclooxygenase. The racemic enantiomer 14g of L-699333 is the most potent enantiomer to date, with inhibitory effects similar to those of the known MK-0591, which has been shown in clinical trials to inhibit the biochemical effects of LTB4 biosynthesis in vitro and LTE4 excretion in urine.
Cat. No.: HY-113628
CAS No.: 189498-57-5
Synonyms: VML-530
Target:
Research Areas:
ABT-080 is an orally active inhibitor of leukotriene biosynthesis that targets 5-lipoxygenase-activating protein (FLAP). ABT-080 inhibits leukotriene production in intact human neutrophils, mouse peritoneal macrophages and human whole blood, with IC50 values of 20 nM, 0.16 nM and 13 μM, respectively. ABT-080 blocks the leukotriene pathway leading to the synthesis of LTB4 and LTC4, but does not block PGH2 biosynthesis. ABT-080 inhibits leukotriene biosynthesis and bronchoconstriction in mouse models. ABT-080 is used in research related to asthma, pleurisy and allergy .
Cat. No.: HY-167939
CAS No.: 788821-30-7
Target:
Research Areas:
(R)-Bambuterol is a β2-receptor agonist with anti-asthmatic and colitis-improving activity. (R)-Bambuterol is indicated for the treatment of asthma and chronic obstructive pulmonary disease and has the advantage of a once-daily dosing and a favorable side effect profile. (R)-Bambuterol significantly reduced disease severity in a mouse model of colitis, more effectively than (RS)-Bambuterol or (S)-Bambuterol. (R)-Bambuterol can significantly reduce the levels of inflammatory cytokines and reduce the infiltration of macrophages in mice with colitis. (R)-Bambuterol also increases β2-adrenoceptor levels and reduces the expression of IL-6, IL-17 and other related proteins in colon tissue in a dose-dependent manner .
Cat. No.: HY-113166R
CAS No.: 25518-54-1
Synonyms: (-)-Lauroylcarnitine (Standard)
Cat. No.: HY-180419
CAS No.: 1883721-73-0
Research Areas:
SF-3-030 is a potent, selective and non-ATP competitive ERK1/2 inhibitor. SF-3-030 selectively induces apoptosis in melanoma cells containing mutated BRaf and constitutively active ERK1/2 signalling. SF-3-030 mitigates multiple features of asthma in a murine model of asthma. SF-3-030 can be used for the research of asthma and melanomasup .
Cat. No.: HY-182693
CAS No.: 2019223-60-8
Research Areas:
CPL302-253 is a PI3Kδ inhibitor with an IC50 of 12.20 nM and a human Kd of 0.85 nM. CPL302-253 functionally regulates PI3Kδ activity, blocks the production of IFNγ, IL-33 and ROS in immune cells, and affects immune function. CPL302-253 blocks the progression of asthma-inducing inflammatory responses in a mouse model of asthma. CPL302-253 can be used for research related to asthma .
Cat. No.: HY-126980
CAS No.: 224054-76-6
Target:
Research Areas:
AMG-126737 is an orally active and highly selective human mast cell tryptase inhibitor with a Ki of 90 nM. AMG-126737 suppresses early/late-phase bronchoconstriction in sheep models. AMG-126737 is promising for research of asthma and allergic diseases .
Cat. No.: HY-182736
CAS No.: 671205-14-4
Target:
Research Areas:
YM-344484 is an orally active dual antagonist of chemokine CCR3 receptor and histamine histamine H1 receptor. YM-344484 inhibits ligand-induced Ca 2+ influx, chemotaxis of CCR3-expressing cells, histamine-induced Ca 2+ influx, increased vascular permeability and eosinophil accumulation. YM-344484 suppresses vascular permeability and inhibits eosinophil infiltration in a mouse asthma model. YM-344484 can be used in research related to asthma, allergic rhinitis and atopic dermatitis .
Cat. No.: HY-P992474
Target:
Research Areas:
TAVO101 is a humanized anti-TSLP antibody with an EC50 of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis .
Cat. No.: HY-136692
CAS No.: 479203-71-9
Target:
Research Areas:
HMR 1031 is a very late antigen-4 (VLA4, i.e., integrin α4β1) inhibitor, with IC50 values of 0.7 nM and 0.3 nM against VLA-4/VCAM-1 and VLA-4/fibronectin, respectively. HMR 1031 blocks allergen-induced airway responses and airway inflammation in mouse and sheep models. HMR 1031 can be used in asthma-related research .
Cat. No.: HY-180411
CAS No.: 146461-98-5
Target:
Research Areas:
SM-15178 is a potent, orally active and selective leukotriene B4 (LTB4) receptor antagonist with an IC50 of 0.30 μM. SM-15178 attenuates LTB4 (HY-107608)-induced neutrophil accumulation in mouse skin and bronchoconstriction in guinea pigs. SM-15178 emonstrates significant anti-inflammatory efficacy across multiple animal models of inflammation. SM-15178 can be used for the research of chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, and asthma .
Cat. No.: HY-B1346S
CAS No.: 1217443-24-7
Synonyms: (±)-Glutamine-13C5,15N2,d10; DL-Gl-13C5,15N2,d10
Research Areas:
DL-Glutamine- 13C5, 15N2,d10 ((±)-Glutamine- 13C5, 15N2,d10; DL-Gl- 13C5, 15N2,d10) is the 13C, 15N, d10-labeled DL-Glutamine (HY-B1346). DL-Glutamine ((±)-Glutamine; DL-Gl) is an amino acid metabolite. DL-Glutamine is a plasma metabolic biomarker associated with Treg/Th17 balance in an OVA-induced eosinophilic asthma mouse model. DL-glutamine positively correlates with muscle quality parameters such as muscle water-holding capacity and shear force, and negatively correlates with oxidative stress markers and apoptotic gene expression. DL-Glutamine is associated with periodontal pathogens and oral microbial communities in saliva/serum. DL-Glutamine can be used in research related to asthma, muscle quality, and periodontal disease .
Cat. No.: HY-150298R
CAS No.: 2226636-04-8
Synonyms: CPI-818 (Standard)
Target:
Research Areas:
Soquelitinib (Standard) is the analytical standard of Soquelitinib (HY-150298). This product is intended for research and analytical applications. Soquelitinib (CPI-818) is an orally active and highly selective covalent interleuKin-2-inducible Kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytoKine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function .
Cat. No.: HY-113628A
CAS No.: 189498-56-4
Synonyms: VML-530 free base
Target:
Research Areas:
ABT-080 free base is an orally active inhibitor of leukotriene biosynthesis that targets 5-lipoxygenase-activating protein (FLAP). ABT-080 free base inhibits leukotriene production in intact human neutrophils, mouse peritoneal macrophages and human whole blood, with IC50 values of 20 nM, 0.16 nM and 13 μM, respectively. ABT-080 free base blocks the leukotriene pathway leading to the synthesis of LTB4 and LTC4, but does not block PGH2 biosynthesis. ABT-080 free base inhibits leukotriene biosynthesis and bronchoconstriction in mouse models. ABT-080 is used in research related to asthma, pleurisy and allergy .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
